MOREPENLAB

- Trading window will close from October 1, 2026. - Closure is for considering unaudited financial results for the quarter and half-year ended September 30, 2026. - Window will reopen 48 hours after the declaration of financial results.

- Morepen Laboratories submitted its first U.S. ANDA to the USFDA for Sitagliptin Tablets USP (25 mg, 50 mg, and 100 mg) on September 25, 2026. - This milestone marks the expansion of the company's established API and CDMO expertise into integrated finished dosage development and regulatory filing. - The innovator product, Januvia, recorded worldwide sales of approximately US$1.604 billion in 2025. - The company estimates 24-36 months from submission to progress towards approval and commercial supply.

- Morepen Laboratories received an independent 'CRISIL ESG 60' rating, categorized as 'Adequate', for fiscal 2026 from Crisil ESG Ratings & Analytics Limited on September 21, 2026.

- Morepen Laboratories Limited completed the first phase of its manufacturing capacity expansion program ahead of schedule. - Installed reactor capacity for API and CDMO increased from 535 KL to 614 KL. - This enhances manufacturing readiness for CDMO supplies and supports existing API business.

- Notice of 41st Annual General Meeting (AGM) to be held on Saturday, September 26, 2026, via Video Conferencing/OAVM. - The Board recommended a final dividend of ₹0.20 per equity share for the financial year 2025-26, with the record date set as Saturday, September 19, 2026. - Mr. Sanjay Suri's designation changed from Whole-Time Director to Managing Director, effective July 1, 2026. - Mr. Sushil Suri re-appointed as Chairman & Managing Director for three years, from October 20, 2026, to October 19, 2029. - Timeline for hiving off the Medical Devices Business into Morepen Medipath Limited extended until the 42nd Annual General Meeting in 2027, at a value of ₹197.10 Crores.

- Morepen Laboratories Limited (parent company) subscribed to a rights issue of its wholly-owned subsidiary, Morepen RX Limited (MRX), for 2,00,00,000 equity shares of ₹10 each, totaling ₹20 Crores. - This investment aims to strengthen MRX's capital base and support its business operations. - The parent company continues to hold 100% of MRX's equity share capital.

- Consolidated Revenue ₹570.13 Cr vs ₹425.24 Cr (▲34.07% YoY) - EBITDA ₹87.72 Cr vs ₹28.58 Cr (▲207.08% YoY) - PAT ₹56.35 Cr vs ₹11.41 Cr (▲394.0% YoY) - EBITDA Margin 15.38% vs 6.72% (▲866 bps)

- Consolidated Revenue ₹570.13 Cr vs ₹425.24 Cr (▲34.07% YoY) - EBITDA ₹87.72 Cr vs ₹28.58 Cr (▲206.99% YoY) - PAT ₹56.35 Cr vs ₹11.41 Cr (▲393.99% YoY) - EBITDA Margin 15.38% vs 6.72% (▲866bps) - Board recommended final dividend for FY26, with record date on September 19, 2026. - Re-appointment of Mr. Sushil Suri as Chairman & Managing Director for a period of three years effective from October 20, 2026. - Approved the extension of the timeline for hiving off the Medical Devices Business into a subsidiary, Morepen Medipath Limited, on a slump sale basis.

New Filing detected. See link for details.

- Revenue ₹575.31Cr vs ₹429.33Cr (▲34% YoY) - EBITDA ₹87.72Cr vs ₹28.57Cr (▲207% YoY) - PAT ₹56.35Cr vs ₹11.41Cr (▲394% YoY) - EBITDA Margin 15.25% vs 6.65% (▲860bps)

- Consolidated Revenue ₹570.13Cr vs ₹425.24Cr (▲34.1% YoY) - EBITDA ₹82.53Cr vs ₹24.17Cr (▲241.5% YoY) - PAT ₹56.35Cr vs ₹11.41Cr (▲394.0% YoY) - EBITDA Margin 14.47% vs 5.68% (▲879bps) - Board declared a record date of September 19, 2026, for determining members eligible to receive final dividend for the financial year ended March 31, 2026. - Board approved the re-appointment of Mr. Sushil Suri as Chairman & Managing Director for a 3-year term from October 20, 2026, subject to AGM approval. - Board approved extending the timeline for hiving off the Medical Devices Business into Morepen Medipath Limited on a slump sale basis, subject to AGM approval. - The 41st Annual General Meeting (AGM) will be held on September 26, 2026.

- Wholly-owned subsidiary "Morepen Labs - FZCO" changed its name to "Morepen Labs FZE" effective July 20, 2026. - This change is due to its migration from IFZA to JAFZA, with JAFZA issuing new documents on July 23, 2026.